New drug RPT1G tested in humans for first time
NCT ID NCT06667765
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new oral drug, RPT1G, in 56 healthy adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. Since this is a first-in-human study, it does not aim to treat any disease but to gather essential safety data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RPT1G (oral capsule)
- What could go wrong
- This is a very early, small study in healthy people, so it cannot show whether RPT1G works for any disease. Side effects are possible but unknown at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?